Course Overview
In this heart failure CE course, learners will review the new universal definition of heart failure and the new stages of heart failure. Clyde W. Yancy, MD, MCs will discuss contemporary and emerging therapies of HFrEF, HFmrEF & HFpEF and explore the new therapeutic potential for SGLT2 inhibitors. By the end of the course, you’ll be able to understand the best insight regarding the prevention of heart failure.
Member Cost: $0
Credits: 0.75 CE contact hours, 0.25 CE pharmacology hours
Learning Objectives
1. Review the new universal definition of heart failure.
2. Review the new stages of heart failure.
3. Understand the best insight regarding the prevention of heart failure.
4. Discuss contemporary and emerging therapies of HFrEF, HFmrEF & HFpEF.
5. Explore the new therapeutic potential for SGLT2 inhibitors.
Faculty
- Clyde W. Yancy, MD, MSc

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of PCNA. PCNA is accredited by AANP as an approved provider of nurse practitioner continuing education. Provider number: 030602.